ProShares Ultra Nasdaq Biotechnology

No trades
See on Supercharts

Key stats

Assets under management (AUM)
72.025MUSD
Fund flows (1Y)
−12.092MUSD
Dividends Yield (FY)
0.05%
Discount/Premium to NAV
−0.8%

About ProShares Ultra Nasdaq Biotechnology

Issuer
ProShare Advisors LLC
Brand
ProShares
Expense ratio
0.95%
Home page
Inception date
Apr 7, 2010
Index tracked
NASDAQ / Biotechnology
Management style
Passive
ISIN
US74347R2141
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQs biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returnsfor good or for ill.

Classification

Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharma, biotech & life sciences
Strategy
Exchange-specific
Weighting scheme
Market cap
Selection criteria
NASDAQ - listed
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Cash
Stock breakdown by region
99%0.1%

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy